Transcatheter treatment of hepatocellular carcinoma with doxorubicin-loaded dc bead (DEBDOX): Technical recommendations

Επιστημονική δημοσίευση - Άρθρο Περιοδικού uoadl:3110988 27 Αναγνώσεις

Μονάδα:
Ερευνητικό υλικό ΕΚΠΑ
Τίτλος:
Transcatheter treatment of hepatocellular carcinoma with doxorubicin-loaded dc bead (DEBDOX): Technical recommendations
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Tranarterial chemoembolization (TACE) has been established by a meta-analysis of randomized controlled trials as the standard of care for nonsurgical patients with large or multinodular noninvasive hepatocellular carcinoma (HCC) isolated to the liver and with preserved liver function. Although conventional TACE with administration of an anticancer-in-oil emulsion followed by embolic agents has been the most popular technique, the introduction of embolic drug-eluting beads has provided an alternative to lipiodol-based regimens. Experimental studies have shown that TACE with drug-eluting beads has a safe pharmacokinetic profile and results in effective tumor killing in animal models. Early clinical experiences have confirmed that drug-eluting beads provide a combined ischemic and cytotoxic effect locally with low systemic toxic exposure. Recently, the clinical value of a TACE protocol performed by using the embolic microsphere DC Bead loaded with doxorubicin (DEBDOX; drug-eluting bead doxorubicin) has been shown by randomized controlled trials. An important limitation of conventional TACE has been the inconsistency in the technique and the treatment schedules. This limitation has hampered the acceptance of TACE as a standard oncology treatment. Doxorubicin-loaded DC Bead provides levels of consistency and repeatability not available with conventional TACE and offers the opportunity to implement a standardized approach to HCC treatment. With this in mind, a panel of physicians took part in a consensus meeting held during the European Conference on Interventional Oncology in Florence, Italy, to develop a set of technical recommendations for the use of DEBDOX in HCC treatment. The conclusions of the expert panel are summarized. © 2011 The Author(s).
Έτος δημοσίευσης:
2012
Συγγραφείς:
Lencioni, R.
De Baere, T.
Burrel, M.
Caridi, J.G.
Lammer, J.
Malagari, K.
Martin, R.C.G.
O'Grady, E.
Real, M.I.
Vogl, T.J.
Watkinson, A.
Geschwind, J.-F.H.
Περιοδικό:
CardioVascular and Interventional Radiology
Τόμος:
35
Αριθμός / τεύχος:
5
Σελίδες:
980-985
Λέξεις-κλειδιά:
debdox; doxorubicin; iodinated poppyseed oil; microsphere; nonionic contrast medium; unclassified drug, artery catheter; chemoembolization; computer assisted tomography; drug delivery system; drug eluting bead; drug megadose; hepatic artery; human; liver cell carcinoma; loading drug dose; nuclear magnetic resonance imaging; particle size; priority journal; review; treatment failure; treatment planning; treatment response; tumor volume, Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Doxorubicin; Drug Carriers; Drug Implants; Humans; Liver Neoplasms
Επίσημο URL (Εκδότης):
DOI:
10.1007/s00270-011-0287-7
Το ψηφιακό υλικό του τεκμηρίου δεν είναι διαθέσιμο.